How multi-omic technologies can help define paediatric undifferentiated systemic autoinflammatory diseases: the experience of the European PerSAIDs consortium
Camilla Speziani, Serena Palmeri, Paolo Uva, Simona Gattulli, Giacomo Cavalca, Andrea Petretto, Federica Penco, Yulia Rodina, Giada Recchi, Banu Balci-Peynircioglu, Ezgi Deniz Batu, Sabrina Fuehner, Enrique Ozcariz, Federica Rizzi, Sergio Decherchi, Klemens Vierlinger, Marco Gattorno, Seza Ozen, Dirk Foell, Juan Ignacio Arostegui, Isabella CeccheriniSystemic AutoInflammatory Diseases (SAIDs) are rare conditions characterised by impaired control of inflammatory and innate immune responses. Precision medicine is already well established for monogenic SAIDs, while personalised approaches remain elusive for those conditions with not identified genetic cause, collectively named undifferentiated SAIDs (uSAIDs).
The multi-omic approach integrates findings from various ‘omics’” technologies (eg, genomics, transcriptomics, proteomics, epigenomics, immunomics), thus representing a potential way of identifying disease-specific biomarkers or complex molecular patterns, offering significant improvements in diagnosis and personalised therapies. At present, significant challenges remain in patient’s sample collection, methodological standardisation and the development of robust bioinformatics tools before the findings can be translated into clinical practice. We provide examples of successful applications of multi-omic analyses to immune-mediated disorders, address the challenges and opportunities associated with multi-omics in paediatric uSAIDs and introduce the ERA PerMed project ‘PerSAIDs’, which combines multi-omic research with artificial intelligence-based decision support solutions to further advance the diagnosis and management of SAIDs.